Publicaciones en las que colabora con MIGUEL ÁNGEL CALLEJA HERNÁNDEZ (12)

2021

  1. Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis

    Pharmacogenetics and Genomics, Vol. 31, Núm. 2, pp. 40-47

  2. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

    Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726

  3. Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis

    Journal of Personalized Medicine, Vol. 11, Núm. 5

2020

  1. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis

    Pathology Research and Practice, Vol. 216, Núm. 4

  2. Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta

    Mutation Research - Reviews in Mutation Research, Vol. 785

2018

  1. Pharmacogenetic biomarkers of response in Crohn's disease

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 1-13

2017

  1. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis

    Surgical Oncology, Vol. 26, Núm. 4, pp. 473-482

  2. Liquid chromatography tandem mass spectrometric determination of triterpenes in human fluids: Evaluation of markers of dietary intake of olive oil and metabolic disposition of oleanolic acid and maslinic acid in humans

    Analytica Chimica Acta, Vol. 990, pp. 84-95

2016

  1. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients

    Pharmacological Research, Vol. 108, pp. 111-118

  2. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients

    Pharmacological Research, Vol. 113, pp. 71-80

2015

  1. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer

    Pharmacogenomics, Vol. 16, Núm. 12, pp. 1411-1426

  2. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

    Breast Cancer Research and Treatment, Vol. 153, Núm. 3, pp. 493-505